Menu Search
Equities

Bonus Biogroup Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BONS:TLV

Bonus Biogroup Ltd

Actions
IndustrialsConstruction and Materials
  • Price (ILa)50.20
  • Today's Change-1.50 / -2.90%
  • Shares traded1.88m
  • 1 Year change+193.57%
  • Beta1.5291
Data delayed at least 20 minutes, as of Feb 17 2026 15:24 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Bonus Biogroup Ltd, formerly Oceana Advanced Industries Ltd, is an Israel-based product-focused biotechnology company applying technology for supplying bone regeneration tissues. The Company is developing cell therapy products based on autologous and allogeneic bone implants that will enable efficient bone transplant and provide cellular-based bone replacement prosthetics for repairing bone lesions. It is targeting a worldwide market for the treatment of major disorders such as bone and cartilage related arthritis, osteoporosis, and various types of bones and joint trauma such as hip fractures and knee injuries, among others. On April 29, 2012, Bonus Bio Group Ltd fully acquired Bonus Therapeutic Ltd.

  • Revenue in ILS (TTM)0.00
  • Net income in ILS-25.52m
  • Incorporated1981
  • Employees49.00
  • Location
    Bonus Biogroup LtdMatamHAIFA 3190501IsraelISR
  • Phone+972 732067100
  • Fax+972 732067111
  • Websitehttps://bonus-bio.com/
More ▼

Institutional shareholders

0.21%Per cent of shares held by top holders
HolderShares% Held
Harel Mutual Funds Ltd.as of 27 Nov 20251.29m0.11%
KSM Mutual Funds Ltd.as of 27 Nov 20251.12m0.10%
Data from 30 Nov 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.